Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 9Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Skin Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Klatskin Tumor 1Glioma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Eye Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7trametinib 5pembrolizumab 5selpercatinib 4dabrafenib 4Specimen Handling 4Nivolumab 4cabozantinib 3Iodine-131 3spartalizumab 2omipalisib 2lenvatinib 2durvalumab 2binimetinib 2Vemurafenib 2Sorafenib 2Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1sapanisertib 1relatlimab 1regorafenib 1pertuzumab 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Neoplasms × binimetinib × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Providence Health & Services

Phase 2 Active not recruiting
24 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡